Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.

Article Details

Citation

Copy to clipboard

Shumaker AC, Bullard HM, Churpek J, Knoebel RW

Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.

J Oncol Pharm Pract. 2019 Oct;25(7):1758-1761. doi: 10.1177/1078155218801055. Epub 2018 Sep 27.

PubMed ID

30259783 [ View in PubMed

]

Abstract

Drug-drug interactions between digoxin and the triazole antifungal agents, mediated via various cytochrome P450 isozymes, have been described in the literature. Posaconazole is not extensively metabolized by these isozymes but is both a p-glycoprotein (P-gp) substrate and inhibitor. To our knowledge, there have been no published cases of clinically significant posaconazole-digoxin drug-drug interactions. We report an interaction between posaconazole (300 mg by mouth daily) and digoxin (0.25 mg by mouth daily, Monday through Friday) resulting in atrial fibrillation with slow ventricular response and degenerating into polymorphic ventricular tachycardia.

DrugBank Data that Cites this Article

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Posaconazole	P-glycoprotein 1	Protein	Humans	Unknown	Substrate Inhibitor	Details